Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2-(4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl)ethyl)dimethylsulfonium P-toluenesulfonate
2. Ipd 1151t
3. Ipd-1151t
1. Suplatast Tosylate
2. 94055-76-2
3. Ipd 1151t
4. Ipd-1151t
5. Suplatast (tosilate)
6. Suplatasttosilate
7. Suplatast Tosilate [inn]
8. 94055-76-2 (tosylate)
9. C9j89787u1
10. (3-((4-(3-ethoxy-2-hydroxypropoxy)phenyl)amino)-3-oxopropyl)dimethylsulfonium 4-methylbenzenesulfonate
11. Dsstox_cid_25003
12. Dsstox_rid_80646
13. Dsstox_gsid_45003
14. [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate
15. Sulfonium, (3-((4-(3-ethoxy-2-hydroxypropoxy)phenyl)amino)-3-oxopropyl)dimethyl-, Salt With 4-methylbenzenesulfonic Acid (1:1)
16. Suplatastum Tosilas
17. Cas-94055-76-2
18. Ccris 6596
19. Tosilate De Suplatast
20. Tosilato De Suplatast
21. Suplatastum Tosilas [inn-latin]
22. Ncgc00181000-01
23. Tosilate De Suplatast [inn-french]
24. Tosilato De Suplatast [inn-spanish]
25. Unii-c9j89787u1
26. [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethylsulfonium 4-methylbenzenesulfonate
27. Mfcd00867604
28. Ym-672
29. Ipd (tn)
30. (+-)-(2-(4-(3-ethoxy-2-hydroxypropoxy)phenyl)carbamoyl)ethyldimethylsulfonium P-tosylate
31. Schembl29042
32. Mls006010745
33. Suplatast Tosilate (jan/inn)
34. Chembl115435
35. Suplatast Tosylate [mi]
36. Dtxsid9045003
37. Suplatast Tosilate [jan]
38. Hms3413p08
39. Hms3655l09
40. Hms3677p08
41. Suplatast Tosilate [mart.]
42. Amy40561
43. Bcp10310
44. Suplatast Tosilate [who-dd]
45. Tox21_112652
46. S2015
47. Suplatast Tosylate, >=98% (hplc)
48. Akos015900359
49. Tox21_112652_1
50. Ccg-269685
51. Cs-0574
52. Ks-1288
53. Ncgc00181000-02
54. (+-)-(2-((p-(3-ethoxy-2-hydroxypropoxy)phenyl)carbamoyl)ethyl)dimethylsulfonium P-toluenesulfonate
55. Hy-17002
56. Smr004701701
57. Ft-0650625
58. S0875
59. Sw219352-1
60. C77240
61. D01423
62. Q7644399
63. 2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyldimethylsulfonium P-toluenesulfonate
64. (3-(4-(3-ethoxy-2-hydroxypropoxy)phenylamino)-3-oxopropyl)dimethylsulfonium 4-methylbenzenesulfonate
Molecular Weight | 499.6 g/mol |
---|---|
Molecular Formula | C23H33NO7S2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 10 |
Exact Mass | 499.16984474 g/mol |
Monoisotopic Mass | 499.16984474 g/mol |
Topological Polar Surface Area | 134 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 500 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Histamine Antagonists
Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. (See all compounds classified as Histamine Antagonists.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17336
Submission : 2004-04-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17336
Submission : 2004-04-12
Status : Inactive
Type : II
About the Company : Lifecare Labs specializes in producing bulk drugs (APIs) and intermediates that adhere to the industry's stringent quality parameters. Its objective is to deliver excellence throug...
About the Company : With “Health for Humanity” and “Infinite Possibilities of the Development of Chemical Science and Technology” as our visions, Iwaki Seiyaku Company Ltd. has been always str...
Market Place
ABOUT THIS PAGE
A Suplatast Tosilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Suplatast Tosilate, including repackagers and relabelers. The FDA regulates Suplatast Tosilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Suplatast Tosilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Suplatast Tosilate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Suplatast Tosilate supplier is an individual or a company that provides Suplatast Tosilate active pharmaceutical ingredient (API) or Suplatast Tosilate finished formulations upon request. The Suplatast Tosilate suppliers may include Suplatast Tosilate API manufacturers, exporters, distributors and traders.
click here to find a list of Suplatast Tosilate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Suplatast Tosilate DMF (Drug Master File) is a document detailing the whole manufacturing process of Suplatast Tosilate active pharmaceutical ingredient (API) in detail. Different forms of Suplatast Tosilate DMFs exist exist since differing nations have different regulations, such as Suplatast Tosilate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Suplatast Tosilate DMF submitted to regulatory agencies in the US is known as a USDMF. Suplatast Tosilate USDMF includes data on Suplatast Tosilate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Suplatast Tosilate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Suplatast Tosilate suppliers with USDMF on PharmaCompass.
Suplatast Tosilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Suplatast Tosilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Suplatast Tosilate GMP manufacturer or Suplatast Tosilate GMP API supplier for your needs.
A Suplatast Tosilate CoA (Certificate of Analysis) is a formal document that attests to Suplatast Tosilate's compliance with Suplatast Tosilate specifications and serves as a tool for batch-level quality control.
Suplatast Tosilate CoA mostly includes findings from lab analyses of a specific batch. For each Suplatast Tosilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Suplatast Tosilate may be tested according to a variety of international standards, such as European Pharmacopoeia (Suplatast Tosilate EP), Suplatast Tosilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Suplatast Tosilate USP).
LOOKING FOR A SUPPLIER?